Condition: Acute Myeloid Leukemia · Sponsor: AbbVie
Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't respond to treatment. This study will assess the adverse events and how pivekimab sunirine moves through the body in pediatric participants with relapsed or refractory (R/R) AML. Pivekimab sunirine is a drug being evaluated in the treatment of AML. This is an open label, single arm study, participants will be enrolled in 1 of the 3 cohorts based on their age and will receive pivekimab sunirine at a dose based on their weight. Around 18 pediatric participants with a diagnosis of AML will be enrolled in the study at approximately 30 sites around the world. Participants will receive intravenous (IV) pivekimab sunirine alone. The total study duration is approximately 28 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Lucile Packard Children's Hospital /ID# 276015 | Palo Alto, California, United States | Recruiting |
| New York Medical College /ID# 275597 | Valhalla, New York, United States | Recruiting |
| Tristar Centennial Medical Center /ID# 275831 | Nashville, Tennessee, United States | Recruiting |
| Perth Children'S Hospital /ID# 275673 | Perth, Western Australia, Australia | Recruiting |
| Ospedale Pediatrico Bambino Gesù /ID# 275692 | Rome, Roma, Italy | Recruiting |
| Seoul National University Hospital /ID# 276978 | Seoul, Seoul Teugbyeolsi, South Korea | Recruiting |
| Samsung Medical Center /ID# 276979 | Seoul, Seoul Teugbyeolsi, South Korea | Recruiting |
| National Taiwan University Hospital /ID# 276635 | Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07306832